Expression Levels of KPNB1 and MERTK in NSCLS Tissues and Correlation with the Clinical Pathological Features and the Prognosis of Progression Free Survival
10.3969/j.issn.1671-7414.2025.01.010
- VernacularTitle:非小细胞肺癌组织中KPNB1,MERTK的表达水平与临床病理特征的相关性及无进展生存预后的研究
- Author:
Surong LIU
1
;
Yang QUAN
;
Jiao ZHU
;
Juan LIU
;
Jingjing LIU
;
Yan LIU
Author Information
1. 兵器工业五二一医院肿瘤内科,西安 710065
- Publication Type:Journal Article
- Keywords:
non-small cell lung cancer;
karyopherin β1;
Mer receptor tyrosine kinase;
progression-free survival
- From:
Journal of Modern Laboratory Medicine
2025;40(1):53-58
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the expression levels of karyopherin β1(KPNB1) and Mer receptor tyrosine kinase (MERTK) in non-small cell lung cancer (NSCLC) tissues and their correlation with clinical pathological features,as well as the prognosis of progression-free survival. Methods A total of 118 NSCLC patients who visited Ordnance Industry 521 Hospital from February 2018 to February 2020 were selected. Immunohistochemical methods were used to detect the expression of KPNB1 and MERTK in NSCLC cancer and paracancer tissue. Kaplan-Meier survival curve analysis was conducted to assess the impact of KPNB1 and MERTK on the progression-free survival prognosis of NSCLC patients. COX regression analysis was performed to identify factors affecting the prognosis of progression-free survival in NSCLC patients. Results The positive rates of KPNB1 (61.02％) and MERTK (62.71％) in cancer tissues were higher than those in adjacent tissues (8.48％,6.78％),and the differences were statistically significant (x2=69.945,81.408,all P<0.001). There was a significant positive correlation between KPNB1 and MERTK expression in the organization (r=0.744,P<0.001). The positive rates of KPNB1(84.21％,82.50％),MERTK (84.21％,85.00％)in NSCLC tissues with lymph node metastasis and TNM stage ⅢA were higher than those without lymph node metastasis(50.00％,52.50％) and TNM stage Ⅰ～Ⅱ(50.00％,51.28％),and the differences were statistically significant (x2=11.078～12.855,all P<0.001). The 3-year progression-free survival rates of KPNB1and MERTK positive and negative groups were 26.39％ (19/72) and 56.52％ (26/46),27.03％ (20/74) and 56.82％ (25/44),respectively,with statistically significant differences (Log Rankx2=0.980,8.463,P=0.001,0.004) . KPNB1 positive,MERTK positive,lymph node metastasis and TNM stage ⅢA were risk factors for progression free survival prognosis in NSCLC patients (waldx2=7.810～10.906,all P<0.001). Conclusion The expression of KPNB1 and MERTK is elevated in NSCLC,both of which are related to TNM staging and lymph node metastasis. They are new biomarkers for evaluating the progression-free survival prognosis of NSCLC.
